These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 12842328)

  • 1. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy.
    Calza L; Manfredi R; Farneti B; Chiodo F
    Int J Antimicrob Agents; 2003 Jul; 22(1):54-9. PubMed ID: 12842328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
    Montes ML; Pulido F; Barros C; Condes E; Rubio R; Cepeda C; Dronda F; Antela A; Sanz J; Navas E; Miralles P; Berenguer J; Pérez S; Zapata A; González-García JJ; Peña JM; Vázquez JJ; Arribas JR
    J Antimicrob Chemother; 2005 May; 55(5):800-4. PubMed ID: 15761071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen.
    Badiou S; De Boever CM; Dupuy AM; Baillat V; Cristol JP; Reynes J
    AIDS; 2003 Mar; 17(5):772-4. PubMed ID: 12646808
    [No Abstract]   [Full Text] [Related]  

  • 4. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra).
    Lafeuillade A; Hittinger G; Philip G; Lambry V; Jolly P; Poggi C
    HIV Clin Trials; 2004; 5(6):392-8. PubMed ID: 15682352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.
    Calza L; Manfredi R; Chiodo F
    J Antimicrob Chemother; 2004 Jan; 53(1):10-4. PubMed ID: 14645323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings.
    Matoga MM; Hosseinipour MC; Aga E; Ribaudo HJ; Kumarasamy N; Bartlett J; Hughes MD;
    Antivir Ther; 2017; 22(3):205-213. PubMed ID: 27740537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.
    Martínez E; Domingo P; Galindo MJ; Milinkovic A; Arroyo JA; Baldovi F; Larrousse M; León A; de Lazzari E; Gatell JM
    Clin Infect Dis; 2004 Apr; 38(7):1017-23. PubMed ID: 15034836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
    Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
    Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
    Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
    Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management.
    Calza L; Manfredi R; Chiodo F
    Int J Antimicrob Agents; 2003 Aug; 22(2):89-99. PubMed ID: 12927947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children.
    Hazra R; Cohen RA; Gonin R; Monteiro JP; Hofer CB; Negra MD; Ruz NP;
    AIDS; 2012 Jan; 26(2):235-40. PubMed ID: 22008654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.
    McComsey G; Bhumbra N; Ma JF; Rathore M; Alvarez A;
    Pediatrics; 2003 Mar; 111(3):e275-81. PubMed ID: 12612284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study.
    Calza L; Colangeli V; Manfredi R; Legnani G; Tampellini L; Pocaterra D; Chiodo F
    AIDS; 2005 Jul; 19(10):1103-5. PubMed ID: 15958843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of hyperlipidemia in HIV-infected subjects receiving lopinavir/ritonavir.
    Bongiovanni M; Bini T; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Biasi P; Adorni F; Monforte AD
    AIDS Res Hum Retroviruses; 2006 Feb; 22(2):132-8. PubMed ID: 16478394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study.
    Bongiovanni M; Bini T; Tordato F; Cicconi P; Melzi S; Repetto D; Sollima S; Rusconi S; d'Arminio Monforte A
    J Antimicrob Chemother; 2003 Jan; 51(1):171-4. PubMed ID: 12493805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiating hyperlipidaemia associated with antiretroviral therapy.
    Mauss S; Stechel J; Willers R; Schmutz G; Berger F; Richter WO
    AIDS; 2003 Jan; 17(2):189-94. PubMed ID: 12545078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.